ChemoCentryx, Inc.
CCXI · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $3 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $3 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 115.5% | 109.1% | -85.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.2% | 96.2% | 88.4% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -255.4% | -677.7% | -1,695.1% | -116.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -274.1% | -718.2% | -1,370.4% | -126.1% |
| EPS Diluted | -0.45 | -0.55 | -0.51 | -0.32 |
| % Growth | 18.2% | -7.8% | -59.4% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |